Assuntos
Gonadotropina Coriônica/farmacologia , Estriol/farmacologia , Grelina/farmacologia , Células Matadoras Naturais/efeitos dos fármacos , Kisspeptinas/farmacologia , Leptina/farmacologia , Adulto , Antígenos CD/genética , Antígenos CD/metabolismo , Antígeno CD56/genética , Antígeno CD56/metabolismo , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/metabolismo , Células Cultivadas , Feminino , Humanos , Células Matadoras Naturais/metabolismo , Receptor B1 de Leucócitos Semelhante a Imunoglobulina , Receptor 1 Desencadeador da Citotoxicidade Natural/genética , Receptor 1 Desencadeador da Citotoxicidade Natural/metabolismo , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/metabolismo , Receptores Imunológicos/genética , Receptores Imunológicos/metabolismoRESUMO
The paper presents experimental findings of the combined antiinfluenza drug (inactivated influenza vaccine + an interferon inducer - an immunogenetic anstimulator - polysaccharide 1,3beta-glucan). The oral immunization with the drug induces antibody accumulation in the secretions of the upper airway and blood sera in defense titers, interferon synthesis at days 1-3 postadministration, forms murine resistance to infection with homologous and heterologous viruses, enhances the functional activity of alveolar macrophages.
Assuntos
Glucanos/imunologia , Imunização/métodos , Vírus da Influenza A/imunologia , Vacinas contra Influenza/imunologia , Indutores de Interferon/imunologia , Infecções por Orthomyxoviridae/prevenção & controle , beta-Glucanas , Administração Oral , Animais , Combinação de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Glucanos/administração & dosagem , Imunidade Inata , Vacinas contra Influenza/administração & dosagem , Indutores de Interferon/administração & dosagem , Masculino , Camundongos , Infecções por Orthomyxoviridae/imunologia , Vacinas de Produtos Inativados/administração & dosagem , Vacinas de Produtos Inativados/imunologiaRESUMO
Respiratory syncytial (RS) virus is the main cause of severe respiratory infections in newborns and infants during the first year of life. In the recent years, search is under way for chemo- and immune replacement therapy preparations for etiotropic RS-infection therapy. Procedures have been developed to prepare immunoglobulins and Chigain preparations having a target-oriented action. They were clinically tested. There was a positive dynamics in the clinical manifestations of the disease and a positive influence on immunological parameters in children.
Assuntos
Fatores Biológicos/uso terapêutico , Colostro , Imunoglobulinas/uso terapêutico , Imunoterapia , Infecções por Vírus Respiratório Sincicial/terapia , Anticorpos Antivirais/análise , Criança , Pré-Escolar , Humanos , Lactente , Recém-Nascido , Infecções por Vírus Respiratório Sincicial/imunologia , Infecções por Vírus Respiratório Sincicial/virologia , Vírus Sinciciais Respiratórios/imunologiaRESUMO
Eighty nine volunteers were under study. They were immunized by inactivated vaccine from influenza viruses A(H1N1)+A(H3N2) one time or every year during 4 to 6 years. Vaccine in dosage of 0.2 ml was applied intracutaneously. Under detailed clinical study deflections of health were not over standard. Accumulation of antibodies was determined to immunogens of the vaccine and to virus A/Leningrad/X/83(H3N2), which was in epidemic circulation 3 years later. Intensity of relative increase of antibodies with repeated immunization was 1.5 to 2 times lower. Maximum concentrations of antibodies were found in a week after vaccination. Immunization didn't cause change of titres of secretory antibodies and concentration of immunoglobulin isotopes G, M, A and E in sera and secretions.
